TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

NCT03506802 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No Participants Enrolled

Conditions

HLA-A*0201 Positive Cells Present
NY-ESO-1 Positive Tumor Cells Present
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

RADIATION: 18F-FHBG
BIOLOGICAL: Aldesleukin
BIOLOGICAL: Cellular Therapy
PROCEDURE: Computed Tomography
BIOLOGICAL: Filgrastim
OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide
PROCEDURE: Leukapheresis
DRUG: Melphalan
DRUG: Plerixafor
PROCEDURE: Positron Emission Tomography

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]